SWHY's research indicates that WUXI APPTEC (603259.SH) expects a Net income of 9.45 billion yuan for 2024, a year-on-year decrease of 1.63%. Adjusted Net income is expected to be 10.58 billion yuan, a year-on-year decrease of 2.5%. For Q4 2024, adjusted Net income is projected at 3.24 billion yuan, representing a year-on-year growth of 20.4% and a quarter-on-quarter growth of 9.1%, in line with company guidance. The company is experiencing accelerated Order growth, with continued special dividends + buybacks rewarding Shareholders. It offers integrated, end-to-end new drug R&D and production services for the Global pharmaceutical Industry, continually lowering R&D barriers through its unique "CRDMO" and "CTDMO" business models. According to the company's PPT, it is expected that by 2025, the continuing Operating Business revenue will return to double-digit growth, with a year-on-year increase of 10%-15%, and overall revenue reaching 41.5-43 billion, maintaining a "Buy" rating.